Analyst Ratings For TherapeuticsMD (NASDAQ:TXMD)
Today, Oppenheimer reiterated its Buy rating on TherapeuticsMD (NASDAQ:TXMD).
Some recent analyst ratings include
- 3/21/2018-Oppenheimer Reiterated Rating of Buy.
- 3/9/2018-Noble Financial Reiterated Rating of Buy.
- 1/7/2018-Cantor Fitzgerald Reiterated Rating of Buy.
- 11/6/2017-Cowen Reiterated Rating of Outperform.
- 9/26/2017-Jefferies Group Reiterated Rating of Buy.
- 9/8/2017-Morgan Stanley initiated coverage with a Equal Weight rating.
Recent Insider Trading Activity For TherapeuticsMD (NASDAQ:TXMD)
TherapeuticsMD (NASDAQ:TXMD) has insider ownership of 23.92% and institutional ownership of 73.27%.
- On 12/8/2017 Tommy G Thompson, Director, bought 5,000 with an average share price of $6.21 per share and the total transaction amounting to $31,050.00.
- On 8/30/2017 Tommy G Thompson, Director, bought 5,000 with an average share price of $5.99 per share and the total transaction amounting to $29,950.00.
- On 3/11/2016 Cooper C Collins, Director, bought 16,000 with an average share price of $6.23 per share and the total transaction amounting to $99,680.00.
- On 8/25/2015 Angus C Russell, Director, bought 13,500 with an average share price of $5.98 per share and the total transaction amounting to $80,730.00.
- On 6/8/2015 Mitchell Krassan, EVP, sold 30,000 with an average share price of $8.18 per share and the total transaction amounting to $245,400.00.
- On 5/12/2015 Angus C Russell, Director, bought 35,000 with an average share price of $6.15 per share and the total transaction amounting to $215,250.00.
- On 5/11/2015 Tommy G Thompson, Chairman, bought 6,000 with an average share price of $6.09 per share and the total transaction amounting to $36,540.00.
Recent Trading Activity for TherapeuticsMD (NASDAQ:TXMD)
Shares of TherapeuticsMD closed the previous trading session at 5.16 up +0.07 1.27% with 5.070000171661377 shares trading hands.
